BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 31313099)

  • 1. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
    Yalniz FF; Wierda WG
    Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BCL2 for the treatment of lymphoid malignancies.
    Anderson MA; Huang D; Roberts A
    Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
    Vogler M; Walter HS; Dyer MJS
    Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic development and current uses of BCL-2 inhibition.
    Roberts AW
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A BH3 Mimetic for Killing Cancer Cells.
    Green DR
    Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
    Khaw SL; Huang DC; Roberts AW
    Pathology; 2011 Oct; 43(6):525-35. PubMed ID: 21881535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
    Valentin R; Grabow S; Davids MS
    Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BCL-2-like Proteins to Kill Cancer Cells.
    Cory S; Roberts AW; Colman PM; Adams JM
    Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax: Targeting BCL2 in Hematological Cancers.
    Scheffold A; Jebaraj BMC; Stilgenbauer S
    Recent Results Cancer Res; 2018; 212():215-242. PubMed ID: 30069633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA Dysregulation to Identify Novel Therapeutic Targets.
    Croce CM
    Curr Top Microbiol Immunol; 2017; 407():191-203. PubMed ID: 28653191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Progress of Oral BCL-2 Inhibitor Venetoclax in the Treatment of Non-Hodgkin's Lymphoma --Review].
    Guo MQ; Luo XY; Wu HY; Huang YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1622-1626. PubMed ID: 36208277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2 and MCL1 inhibitors for hematologic malignancies.
    Roberts AW; Wei AH; Huang DCS
    Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 20. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.